Genmab — Juni 2019

[Helge_LarsenPI-redaktør]

Sorry i forgårs 8,21 og 9,41.

[E_L]

JNJ-372 https://twitter.com/Jbauml/status/1134526398360670209 or more via search https://twitter.com/search?q=JNJ-372&src=typed_query&f=live

[jkj]

Is JNJ-372 the same as JNJ-61186372 E L ?

[E_L]

yes

[GeorgeBest]

JNJ-372 looks very promissing according this. But the other day there were statements that efficiacy was not overwhelming! What should believe in?

[DevOp]

De var smuttet. Men det ser da i det mindste rigtig godt ud - ligner lidt samme billede, vi har set tidligere med dybere respons og større forskel ift control group, jo længere tid, der går

[peter12]

@GB believe facts (what you see) and not what some people say. If J&J see a blockbuster I believe it though

[Sukkeralf]

GB if it was Ohad Hammer then he is very hard to impress so dont worry

[GeorgeBest]

OK thanks Sukkeralf and peter12. I will stop worrying

[Monforte]

@Bulder 9:34, nej var med i fase II-studiet fra juni 2014
og stoppede i marts 2016 med Rd

[jkj]

intet at finde nogen steder om dagens fremlæggelser fra Genmab.

[GeorgeBest]

Der er i morgen jkj https://twitter.com/janssenus/status/1134882324125032450?s=21

[E_L]

Prof Maria-Victoria Mateos talks to ecancer at
2019 ASCO about the COLOMBA study into subcutaneous versus intravenous dara https://ecancer.org/video/7904/subcutaneous-versus-intravenous-daratumumab-administration-in-patients-with-relapsed-or-refractory-multiple-myeloma.php

[GeorgeBest]

Myeloma. Skyrocketing drug prices https://twitter.com/rfonsi1/status/1134987324377501697?s=21

[E_L]

@Tandfeen-2 Cassiopeia would indeed be the 1st frontline transplant eligable combi, admittedly mostly a european regimen though i think. Next will be Griffin , Dara + VRd, we should get 1st data soon, but i think that is a year behind Cassiopeia

[E_L]

https://twitter.com/Mohty_EBMT/status/1134943201171824640

[peter12]

GB 7:49 interesting article where Rajkumar actually criticise

[peter12]

Revlimid (as I read it) . Also Dr Carlson from ICER says : However, using a cost-effectiveness threshold of $150,000 per quality-adjusted life-year, ICER found that “only the addition of daratumumab or panobinostat may be considered cost-effective options.”

[Nike]

Er der nogen bud på, hvad vi skal forvente os af morgendagen ? Vil vi se optimisme efter ASCO og en bedre forståelse for NASDAQ, eller drukner kursen på ny i handelskrig og Trump-tweets?

[jkj]

svært at spå om pt. vi har jo endnu ikke set nogen data.